Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis.
Matthew G DaveyEoin F CleereJohn P O'DonnellSara GaisorAoife J LoweryMichael J KerinPublished in: Breast cancer research and treatment (2022)
RS testing accurately estimates LRR risk for patients being treated for early-stage ER+/HER2- breast cancer. Future prospective, randomized studies may validate the predictive value of RS in estimating LRR.
Keyphrases
- estrogen receptor
- gene expression
- positive breast cancer
- early stage
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- dna methylation
- prognostic factors
- open label
- clinical trial
- double blind
- randomized controlled trial
- current status
- placebo controlled
- phase ii
- sentinel lymph node
- phase iii
- patient reported